BR112021018156A2 - Antagonistas de ngf para uso médico - Google Patents
Antagonistas de ngf para uso médicoInfo
- Publication number
- BR112021018156A2 BR112021018156A2 BR112021018156A BR112021018156A BR112021018156A2 BR 112021018156 A2 BR112021018156 A2 BR 112021018156A2 BR 112021018156 A BR112021018156 A BR 112021018156A BR 112021018156 A BR112021018156 A BR 112021018156A BR 112021018156 A2 BR112021018156 A2 BR 112021018156A2
- Authority
- BR
- Brazil
- Prior art keywords
- ngf
- medical use
- ngf antagonists
- polypeptides
- trka
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821438P | 2019-03-20 | 2019-03-20 | |
| PCT/US2020/023846 WO2020191289A1 (en) | 2019-03-20 | 2020-03-20 | Ngf antagonists for medical use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021018156A2 true BR112021018156A2 (pt) | 2021-11-16 |
Family
ID=72521232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021018156A BR112021018156A2 (pt) | 2019-03-20 | 2020-03-20 | Antagonistas de ngf para uso médico |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220169740A1 (https=) |
| EP (1) | EP3941933A4 (https=) |
| JP (1) | JP2022525754A (https=) |
| KR (1) | KR20220066002A (https=) |
| CN (1) | CN113840831A (https=) |
| AU (1) | AU2020240120A1 (https=) |
| BR (1) | BR112021018156A2 (https=) |
| CA (1) | CA3133104A1 (https=) |
| MX (1) | MX2021011335A (https=) |
| WO (1) | WO2020191289A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12297272B2 (en) | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| CN120904316A (zh) * | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
| CN115996949A (zh) * | 2020-04-17 | 2023-04-21 | 硕腾服务有限责任公司 | 犬抗体变异体 |
| KR20230005875A (ko) * | 2020-04-22 | 2023-01-10 | 킨드레드 바이오사이언시스, 인코포레이티드 | 수의학 용도를 위한 장시간-작용성 항-il31 항체 |
| AU2022329459A1 (en) | 2021-08-20 | 2024-02-29 | Intervet International B.V. | Antibodies and igg fusion proteins with an extended half-life |
| EP4419547A1 (en) * | 2021-10-21 | 2024-08-28 | Petmedix Ltd. | Proteins comprising the extracellular domain of p75ntr |
| US11608371B1 (en) | 2021-10-21 | 2023-03-21 | Petmedix Ltd | Therapeutic molecules |
| KR20250141832A (ko) * | 2023-02-09 | 2025-09-29 | 펫메딕스 리미티드 | P75 뉴로트로핀 수용체(p75ntr)의 세포외 도메인 변이체를 포함하는 치료 분자 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9807781D0 (en) * | 1998-04-09 | 1998-06-10 | Univ Bristol | Therapeutic agent |
| GB0020504D0 (en) * | 2000-08-18 | 2000-10-11 | Univ Bristol | Therapeutic method |
| MX370489B (es) * | 2004-01-09 | 2019-12-16 | Pfizer | Anticuerpos contra madcam. |
| WO2007059574A1 (en) * | 2005-11-23 | 2007-05-31 | Apollo Life Sciences Limited | A molecule and chimeric molecules thereof |
| US7342146B2 (en) * | 2006-01-11 | 2008-03-11 | Industrial Technology Research Institute | Neurodegenerative non-human transgenic mammal expressing TrkA fusion protein |
| CA2754408A1 (en) * | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| WO2014093387A1 (en) * | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| GB201308738D0 (en) * | 2013-05-15 | 2013-06-26 | Polytherics Ltd | Novel polymer conjugates |
| JPWO2015064621A1 (ja) * | 2013-10-29 | 2017-03-09 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| WO2016035052A1 (en) * | 2014-09-05 | 2016-03-10 | Nvip Pty Ltd | Anti-nerve growth factor antibodies for treating itching |
| US9517238B2 (en) * | 2014-11-07 | 2016-12-13 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammation through inhibition of NTRK1 |
| US12297272B2 (en) * | 2017-08-15 | 2025-05-13 | Eianco US inc. | IgG Fc variants for veterinary use |
| CN120904316A (zh) * | 2018-12-27 | 2025-11-07 | 伊兰科美国公司 | 兽用IgG Fc变体 |
-
2020
- 2020-03-20 US US17/439,972 patent/US20220169740A1/en active Pending
- 2020-03-20 KR KR1020217032766A patent/KR20220066002A/ko not_active Ceased
- 2020-03-20 EP EP20773197.7A patent/EP3941933A4/en active Pending
- 2020-03-20 AU AU2020240120A patent/AU2020240120A1/en not_active Abandoned
- 2020-03-20 WO PCT/US2020/023846 patent/WO2020191289A1/en not_active Ceased
- 2020-03-20 JP JP2021555430A patent/JP2022525754A/ja active Pending
- 2020-03-20 CN CN202080035418.XA patent/CN113840831A/zh active Pending
- 2020-03-20 CA CA3133104A patent/CA3133104A1/en active Pending
- 2020-03-20 MX MX2021011335A patent/MX2021011335A/es unknown
- 2020-03-20 BR BR112021018156A patent/BR112021018156A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020191289A1 (en) | 2020-09-24 |
| MX2021011335A (es) | 2022-01-06 |
| KR20220066002A (ko) | 2022-05-23 |
| US20220169740A1 (en) | 2022-06-02 |
| AU2020240120A1 (en) | 2021-09-30 |
| JP2022525754A (ja) | 2022-05-19 |
| CA3133104A1 (en) | 2020-09-24 |
| EP3941933A1 (en) | 2022-01-26 |
| EP3941933A4 (en) | 2023-07-26 |
| CN113840831A (zh) | 2021-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021018156A2 (pt) | Antagonistas de ngf para uso médico | |
| MX2021004313A (es) | Variantes de fc con union alterada al receptor de fc neonatal (fcrn) para uso veterinario. | |
| NZ757956A (en) | Il4/il13 receptor molecule for veterinary use | |
| MX2021002971A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
| BR112019004733A2 (pt) | métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1 | |
| BRPI0923855A8 (pt) | Ácido lipóico, e, composição de ração de animal de estimação | |
| CY1122987T1 (el) | Αντισωματα εναντι αμυλοειδους βητα | |
| CY1123007T1 (el) | Υποκατεστημενα 4-αζαϊνδολια και χρηση αυτων ως ρυθμιστες υποδοχεα glun2b | |
| CY1111714T1 (el) | Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf). | |
| EA201991643A1 (ru) | Человеческие антитела к токсину гемолизину а s.aureus | |
| CY1120281T1 (el) | Πρωτεϊνες μονης αλυσιδας αγωνιστες των υποδοχεων της trail | |
| BR112021011642A2 (pt) | Variantes de igg fc para uso veterinário | |
| AR061170A1 (es) | Proteinas que se unen con el factor de crecimiento de hepatocitos (hgf) | |
| BR112018074978A2 (pt) | anticorpos para alfa-sinucleína e usos dos mesmos | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| MX2022013149A (es) | Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario. | |
| MX2022002056A (es) | Compuestos para el tratamiento de enfermedad respiratoria bovina o porcina. | |
| BR112012016146A2 (pt) | uso de piruvatos na preparação de composições para animais de estimação | |
| MX2022002360A (es) | Anticuerpos de anti-il31 para uso veterinario. | |
| EP3737333C0 (en) | DEVICE FOR IMPROVING TOPICAL TREATMENTS AGAINST ORAL MUCOSITIS AND OTHER ORAL CONDITIONS | |
| IL281691A (en) | Compositions and methods for feeding domesticated animals | |
| BRPI0923783A8 (pt) | Métodos para induzir perda de gordura corporal, e para aumentar a percentagem de massa de músculo magro em um animal de estimação | |
| BR112018012660A2 (pt) | composto, sal, composto sólido, polimorfo a, polimorfo b, polimorfo c, polimorfo d, composição, método de inibição da atividade de gls1 em uma amostra biológica, métodos de tratamento de um distúrbio mediado por gls1 em um sujeito necessitado, composto, sal, solvato ou polimorfo, e uso de um composto, sal, solvato ou polimorfo | |
| EP3542639C0 (en) | INGREDIENT FOR ANIMAL FEED, FEED AND METHOD FOR FEEDING ANIMALS | |
| BR112019011461A2 (pt) | terapia celular à base de nk melhorada |